- Home
- NQP vs QURE Comparison
NQP vs QURE Comparison
Compare NQP & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NQP
- QURE
- Stock Information
- Founded
- NQP 1990
- QURE 1998
- Country
- NQP United States
- QURE Netherlands
- Employees
- NQP N/A
- QURE N/A
- Industry
- NQP Trusts Except Educational Religious and Charitable
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- NQP Finance
- QURE Health Care
- Exchange
- NQP Nasdaq
- QURE Nasdaq
- Market Cap
- NQP 465.6M
- QURE 432.6M
- IPO Year
- NQP N/A
- QURE 2007
- Fundamental
- Price
- NQP $11.74
- QURE $6.21
- Analyst Decision
- NQP
- QURE Buy
- Analyst Count
- NQP 0
- QURE 6
- Target Price
- NQP N/A
- QURE $17.00
- AVG Volume (30 Days)
- NQP 58.4K
- QURE 757.3K
- Earning Date
- NQP 01-01-0001
- QURE 11-05-2024
- Dividend Yield
- NQP 3.21%
- QURE N/A
- EPS Growth
- NQP N/A
- QURE N/A
- EPS
- NQP N/A
- QURE N/A
- Revenue
- NQP N/A
- QURE $28,587,000.00
- Revenue This Year
- NQP N/A
- QURE $157.96
- Revenue Next Year
- NQP N/A
- QURE N/A
- P/E Ratio
- NQP N/A
- QURE N/A
- Revenue Growth
- NQP N/A
- QURE N/A
- 52 Week Low
- NQP $9.65
- QURE $3.73
- 52 Week High
- NQP $11.89
- QURE $11.35
- Technical
- Relative Strength Index (RSI)
- NQP 34.58
- QURE 47.23
- Support Level
- NQP $11.74
- QURE $6.51
- Resistance Level
- NQP $11.89
- QURE $7.96
- Average True Range (ATR)
- NQP 0.15
- QURE 0.59
- MACD
- NQP 0.01
- QURE -0.04
- Stochastic Oscillator
- NQP 65.43
- QURE 32.76
About NQP Nuveen Pennsylvania Quality Municipal Income Fund
Nuveen Pennsylvania Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal and Pennsylvania income taxes and to enhance portfolio value relative to the municipal bond market by investing in municipal securities that are exempt from federal, Pennsylvania state, and local income taxes. It invests a majority of its assets in securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.